Xiuhua T. Weng

Fuzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

From budget constraints to value-based payment: an incremental cost-effectiveness analysis of sacituzumab tirumotecan for advanced triple-negative breast cancer in China.

From budget constraints to value-based payment: an incremental cost-effectiveness analysis of sacituzumab tirumotecan for advanced triple-negative breast cancer in China.

Journal: Expert review of anticancer therapy

Published: April 30, 2026

The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations.

The pricing barrier: cost-effectiveness of Glofitamab for relapsed/refractory DLBCL in China beyond threshold and value-based pricing strategy considerations.

Journal: Expert review of anticancer therapy

Published: February 24, 2026

Development and validation of a prognostic nomogram for predicting the progression risk of HCC after lenvatinib therapy.

Development and validation of a prognostic nomogram for predicting the progression risk of HCC after lenvatinib therapy.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: February 11, 2026

Does the Combination of Anticoagulants and Angiogenesis Inhibitors Increase the Risk of Bleeding in Cancer Patients?

Does the Combination of Anticoagulants and Angiogenesis Inhibitors Increase the Risk of Bleeding in Cancer Patients?

Journal: Thrombosis and haemostasis

Published: November 07, 2025

Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China.

Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China.

Journal: The pharmacogenomics journal

Published: October 13, 2025

Current status of interventional therapy for hepatic encephalopathy associated with spontaneous portosystemic shunts

Current status of interventional therapy for hepatic encephalopathy associated with spontaneous portosystemic shunts

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: July 15, 2025

The impact of spontaneous portosystemic shunt on clinical outcomes in patients with liver cirrhosis and hepatic encephalopathy

The impact of spontaneous portosystemic shunt on clinical outcomes in patients with liver cirrhosis and hepatic encephalopathy

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: June 18, 2025

Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study.

Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study.

Journal: Scientific reports

Published: April 18, 2025

Is the incidence and burden of cancer increasing among young individuals? An age-related analysis based on Global Burden of Disease Study and Surveillance, Epidemiology and End Results.

Is the incidence and burden of cancer increasing among young individuals? An age-related analysis based on Global Burden of Disease Study and Surveillance, Epidemiology and End Results.

Journal: Internal medicine journal

Published: August 20, 2024

The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.

The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.

Journal: Pharmacogenomics

Published: June 17, 2024

Is Bevacizumab a Cost-Effective Regimen for Treating Cerebral Radiation Necrosis in the United States?

Is Bevacizumab a Cost-Effective Regimen for Treating Cerebral Radiation Necrosis in the United States?

Journal: Practical radiation oncology

Published: April 12, 2024

Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China.

Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: December 12, 2023

Showing 1-12 of 43

Last Updated: 09/26/2026